There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, with different stated mg dose but similar bioavailability, will both be available on the market.
Similar Posts
Professor Bola Owolabi CBE: Creating the Climate for Health Equity
Exploring the MHRA’s transformational impact on access, experience, and outcomes.
Decision: Advertising Investigations: June 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Field Safety Notices: 1 to 5 December 2025
List of Field Safety Notices from 1 to 5 Deceber 2025.
Multi-million pound backing for cutting edge projects by UK scientists and innovators
New government funding will help make the boldest ideas in UK life sciences a reality.
MHRA approves lenacapavir for the prevention of sexually transmitted HIV-1 infection
As with any medicine, the MHRA will keep the safety and effectiveness of lenacapavir under close review.
MHRA Takes Over Chair of International Access Consortium for 2026
The Access Consortium — comprising regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland — works together to streamline regulatory processes, support innovation and improve global public health outcomes.